Caxton Corporation’s ALX Oncology ALXO Stock Holding History

Caxton Corporation’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.4K	Hold	20,946	–	–	2.34%	10
2026 Q1	$42K	Buy	+20,946	New	+$39.9K	1.04%	7

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Caxton Corporation's ALXO Position: Q2 2026 in Review

Caxton Corporation held its ALX Oncology (ALXO) position steady in Q2 2026 at 20,946 shares worth $43.4K. The position accounts for 2.34% of the portfolio, ranked #10.

Caxton Corporation first reported a position in ALXO in Q1 2026 and has held it in 2 quarters since. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

Caxton Corporation held 20,946 shares of ALX Oncology worth $43.4K as of Q2 2026.
Caxton Corporation left its ALX Oncology share count unchanged in Q2 2026.
ALX Oncology made up 2.34% of Caxton Corporation's portfolio in Q2 2026, its #10 holding.
Caxton Corporation first reported a position in ALX Oncology in Q1 2026 and has held it in 2 quarters since.
94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Caxton Corporation's 13F filing for Q2 2026, filed 14 Aug 2026.